Happe Spine’s Integrate-C interbody fusion system has been implanted in more than 1,000 patients across 40 U.S. facilities. The company said the milestone reflects growing clinical adoption of the ...
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback